Abstract
Rates of gonorrhea and chlamydia have continued to rise over the past few years, but unfortunately current testing modalities lead to a lag time of 7-10 days between the initial visit and the test resulting leading to delays in treatment and possible spread of infection. To prevent this, some have opted to treat symptomatically which can lead to both over and undertreatment of gonorrhea and chlamydia, and is also a poor practice for good antibiotic stewardship. With approval of a new point of care (POC) gonorrhea and chlamydia assay by the US Food and Drug Administration (FDA) the researchers wanted to test if the new, 30-minute turn around, testing modality had equivalent performance to the traditional nucleic acid amplification tests (NAATs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
